Skip to main content

Overview of Treatment of Urinary Incontinence

  • Chapter
  • First Online:
Female Pelvic Medicine

Abstract

The most common subtypes of urinary incontinence are stress incontinence, urgency urinary incontinence, and mixed incontinence. Generally, there is a step-wise approach to management with less invasive and lower-risk therapies provided initially including pelvic floor therapy and behavioral modification. For stress urinary incontinence, there are several operative modalities available with midurethral sling being the most commonly used procedure. For overactive bladder (OAB) and urgency urinary incontinence, therapies include medications (anticholinergics and beta-3 agonists) and, if that fails, interventions such as intradetrusor injections of onabotulinumtoxinA and neuromodulation. Mixed urinary incontinence generally includes a multimodal treatment approach with a focus on symptoms that are most bothersome to the patient. This chapter will review incontinence types, evaluation, treatment, and outcomes.

Commentary by John P. Lavelle, Veterans Affairs Palo Alto Health Care System, Department of Surgical Service, Urology Section, Palo Alto, CA, USA

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. NeurourolUrodyn. 2010;29(1):4–20.

    Google Scholar 

  2. Gleason JL, Richter HE, Redden DT, Goode PS, Burgio KL, Markland AD. Caffeine and urinary incontinence in US women. Int Urogynecol J. 2013;24:295–302.

    Article  Google Scholar 

  3. Kenton K. Urinary incontinence in women. Practice bulletin no. 155. American College of Obstetricians and Gynecologists. Obs Gynecol [Internet]. 2015 [cited 2018 Aug 22];126:e66–81. Available from: www.niddk.nih.gov/.

  4. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women a review. JAMA. 2017;318(16):1592–604.

    Article  Google Scholar 

  5. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn [Internet]. 2010 [cited 2018 Sep 29];29:213–40. Available from: www.interscience.wiley.com.

  6. Fitzgerald M, Stablein C, Brubaker L. Urinary habits among asymptomatic women. AJOG. 2002;187:1384–8.

    Article  CAS  Google Scholar 

  7. Hashim H, Mousa R. Management of fluid intake in patients with overactive bladder. Curr Urol Rep. 2009;10:428–33.

    Article  Google Scholar 

  8. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. NeurourolUrodyn. 2004;23:322.

    Google Scholar 

  9. Ubersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. NeurourolUrodyn. 1995;14:131.

    Google Scholar 

  10. Patrick DL, Martin ML, Bushnell DM, et al. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument [I-QOL]. Urology. 1999;53:71.

    Article  CAS  Google Scholar 

  11. Barber MD, Bump RCWM. Short forms of two condition-specific quality of life questionnaires for women with pelvic floor disorders. Am J Obstet Gynecol. 2005;193:103.

    Article  CAS  Google Scholar 

  12. Rogers RG, Coates KW, Kammerer-Doak D, et al. A short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire [PISQ-12]. Int Urogynecol J. 2003;14:164.

    Article  Google Scholar 

  13. Bradley C, Rahn D, Nygaard I, Barber M, Nager C, Kenton KS. The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence. NeurourolUrodyn. 2010;29:727–34.

    Google Scholar 

  14. Sandvik H, Seim A, Vanvik A, Hunskaar S. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. NeurourolUrodyn. 2000;19:137–45.

    CAS  Google Scholar 

  15. Winters JC, Dmochowski RR, Goldman HB, Herndon CDA, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol [Internet]. Elsevier Inc. 2012 [cited 2014 Feb 20];188(6 Suppl):2464–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23098783.

  16. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol [Internet]. Elsevier. 2015 [cited 2018 Sep 30];193(5):1572–80. Available from: https://www-sciencedirect-com.libproxy1.usc.edu/science/article/pii/S0022534715001779.

  17. Fader M, Cottenden AM, Getliffe K. Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2008 [cited 2018 Sep 30];(4). Available from: https://doi.org/10.1002/14651858.CD007408.

  18. van Leijsen SAL, Kluivers KB, Mol BWJ, Milani AL, Roovers J-PWR, et al. Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. Obstet Gynecol [Internet]. 2013 [cited 2014 Feb 17];121(5):999–1008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23635736.

  19. Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J, et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic [Internet]. 2010 [cited 2018 Sep 29]. Available from: https://outlook.office.com/owa/?realm=med.usc.edu&path=/attachmentlightbox.

  20. Kenton K, Norton PA, Sirls LT, Kraus SR, Chai TC, Lemack GE, et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med [Internet]. Massachusetts Medical Society. 2010;362(22):2066–76. Available from: https://doi.org/10.1056/NEJMoa0912658.

  21. Ford A, Rogerson L, Cody J, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev [Internet]. 2015;CD006375(7):1–287. Available from: www.cochranelibrary.com.

  22. Cameron AP, Haraway AM. The treatment of female stress urinary incontinence: an evidenced-based review. Open access J Urol [Internet]. Dove Press. 2011 [cited 2018 Sep 30];3:109–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24198643.

  23. Ostaszkiewicz J, Johnston L, Roe B. Timed voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2004 [cited 2018 Sep 30];(1). Available from: https://doi.org/10.1002/14651858.CD002802.pub2.

  24. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2004 [cited 2018 Sep 30];(1). Available from: https://doi.org/10.1002/14651858.CD001308.pub2.

  25. Dumoulin C, Hay-Smith EJC, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev [Internet]. 2014 [cited 2018 Sep 30]. Available from: www.cochranelibrary.com.

  26. Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson K-E, et al. Can incontinence be cured? A systematic review of cure rates. [cited 2018 Sep 29]. Available from: https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-017-0828-2.

  27. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. PRIDE Investigators. N Engl J Med. 2009;360:481–90.

    Article  CAS  Google Scholar 

  28. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA [Internet]. American Medical Association; 2005 [cited 2018 Sep 30];293(8):935. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.293.8.935.

  29. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2012 [cited 2018 Sep 30];(10). Available from: https://doi.org/10.1002/14651858.CD001405.pub3.

  30. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol [Internet]. Elsevier. 2003 [cited 2018 Sep 30];170(4):1259–63. Available from: https://www-sciencedirect-com.libproxy2.usc.edu/science/article/pii/S0022534705631412.

  31. Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner A, et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence. Obstet Gynecol [Internet]. 2010 [cited 2018 Sep 29];115(3):609–17. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006250-201003000-00020.

  32. Samuels JB, Garcia MA. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesthetic Surg J [Internet]. 2018 [cited 2018 Sep 30]. Available from: https://academic.oup.com/asj/advance-article/doi/10.1093/asj/sjy087/4992010.

  33. Walter J, Larochelle A. No. 358-intravaginal laser for genitourinary syndrome of menopause and stress urinary incontinence- clinical key. JOGC [Internet]. 2018 [cited 2018 Sep 30];40(4):503–11. Available from: https://www-clinicalkey-com.libproxy2.usc.edu/#!/content/playContent/1-s2.0-S1701216317312082?returnurl=null&referrer=null.

  34. Nager CW, Sirls L, Litman HJ, Richter H, Nygaard I, Chai T, et al. Baseline urodynamic predictors of treatment failure 1 year after mid urethral sling surgery. J Urol [Internet]. American Urological Association Education and Research, Inc. 2011;186(2):597–603. Available from: https://doi.org/10.1016/j.juro.2011.03.105.

  35. Mamut A, Carlson KV. Periurethral bulking agents for female stress urinary incontinence in Canada. Can Urol Assoc J [Internet]. Canadian Urological Association. 2017 [cited 2018 Sep 30];11(6S2):152. Available from: http://www.cuaj.ca/index.php/journal/article/view/4612.

  36. Jonsson Funk M, Levin PJ, Wu JM. Trends in the surgical management of stress urinary incontinence. Obstet Gynecol [Internet]. NIH Public Access. 2012 [cited 2018 Sep 30];119(4):845–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22433349.

  37. Brubaker L, Richter HE, Norton PA, Albo M, Zyczynski HM, Chai TC, et al. 5-year continence rates, satisfaction and adverse events of burch urethropexy and fascial sling surgery for urinary incontinence. J Urol [Internet]. NIH Public Access. 2012 [cited 2018 Sep 30];187(4):1324–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22341290.

  38. Lapitan MCM, Cody JD, Mashayekhi A. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2017 [cited 2018 Oct 17];(7). Available from: https://doi.org/10.1002/14651858.CD002912.pub7.

  39. Michael A, Richter H, Brubaker L, Norton P, Kraus S, Philippe Z, Chai T, Zyczynski H, Diokno A, Tennstedt S. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med. 2007;356(21):2143–54.

    Article  Google Scholar 

  40. Schimpf MO, Rahn DD, Wheeler TL, Patel M, White AB, Orejuela FJ, et al. Sling surgery for stress urinary incontinence in women: a systematic review and metaanalysis. Am J Obstet Gynecol [Internet]. Mosby. 2014 [cited 2018 Sep 30];211(1):71.e1–71.e27. Available from: https://www.sciencedirect.com/science/article/pii/S0002937814000593.

  41. Brubaker L, Cundiff GW, Fine P, Nygaard I, Richter HE, Visco AG, et al. Abdominal sacrocolpopexy with burch colposuspension to reduce urinary stress incontinence [Internet]. N Engl J Med. 2006 [cited 2018 Sep 30]. 354. Available from: www.nejm.org.

  42. Patel H, Ostergard DR, Sternschuss G. Polypropylene mesh and the host response. [cited 2018 Sep 29]. Available from: http://2015.iuga.org/wp-content/uploads/workshops/ws29_literature1.pdf.

  43. Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. In: Ogah J, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd. 2009 [cited 2018 Sep 30]:CD006375. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19821363.

  44. Kenton K, Stoddard AM, Zyczynski HM, Albo ME, Rickey L, Norton PA, et al. 5-year longitudinal follow-up after retropubic and transobturator midurethral slings. J Urol. 2015;193(1):203–10.

    Article  Google Scholar 

  45. Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2017 [cited 2018 Oct 17];(7). Available from: https://doi.org/10.1002/14651858.CD006375.pub4.

  46. Nambiar A, Cody JD, Jeffery ST, Aluko P. Single-incision sling operations for urinary incontinence in women. Cochrane Database Syst Rev [Internet]. John Wiley & Sons, Ltd. 2017 [cited 2018 Sep 30];(7). Available from: https://doi.org/10.1002/14651858.CD008709.pub3.

  47. McCoy O, Vaughan T, Nickles SW, Ashley M, MacLachlan LS, Ginsberg D, et al. Outcomes of autologous fascia pubovaginal sling for patients with transvaginal mesh related complications requiring mesh removal. J Urol [Internet]. Elsevier. 2016 [cited 2018 Sep 30];196(2):484–9. Available from: https://www-sciencedirect-com.libproxy2.usc.edu/science/article/pii/S0022534716034649.

  48. Weber AM. Pelvic organ prolapse. Obstet Gynecol. 2005;106(3):615–34.

    Article  Google Scholar 

  49. Brubaker L, Cundiff G, Fine P, Nygaard I, Richter H, Visco A, et al. A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods. Control Clin Trials. 2003;24(5):629–42.

    Article  CAS  Google Scholar 

  50. Kirby AC, Kellogg ES. Trends in utilization of third-line therapies for non-neurogenic overactive bladder: sacral neuromodulation, peripheral tibial nerve stimulation, and intradetrusor onabotulinumtoxinA. 2018 [cited 2018 Sep 30];13:25–30. Available from: https://doi.org/10.1007/s11884-018-0462-7.

  51. Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol [Internet]. 2015 [cited 2018 Oct 1];193(5):1572–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25623739.

  52. Ackerman AL, Lai HH, Parameshwar PS, Eilber KS, Anger JT. Symptomatic overlap in overactive bladder and interstitial cystitis/painful bladder syndrome - development of a new algorithm. BJU Int [Internet]. 2018 [cited 2018 Oct 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30253040.

  53. Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women. Obstet Gynecol [Internet]. 2015 [cited 2018 Sep 30];125(6):1423–32. Available from: http://insights.ovid.com/crossref?an=00006250-201506000-00022.

  54. Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol [Internet]. 2009 [cited 2018 Sep 29];65:309–14. Available from: https://search-proquest-com.libproxy2.usc.edu/docview/214487128?accountid=14749.

  55. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc [Internet]. Wiley/Blackwell (10.1111). 2015 [cited 2018 Sep 30];63(11):2227–46. Available from: https://doi.org/10.1111/jgs.13702.

  56. American Urogynecologic Society (AUGS) Guidelines Committee, Thomas T, Walter M. AUGS consensus statement: association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg [Internet]. 2017;23(3):177–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28441276.

  57. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol [Internet]. 2016 [cited 2018 Sep 30];73(6):721. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27088965.

  58. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol [Internet]. Elsevier. 2017 [cited 2018 Sep 30];72(3):389–99. Available from: https://www-sciencedirect-com.libproxy1.usc.edu/science/article/pii/S0302283817300623.

  59. Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol [Internet]. 2017 [cited 2018 Oct 1];35(5):827–38. Available from: https://doi.org/10.1007/s00345-016-1908-1.

  60. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol [Internet]. 2016 [cited 2018 Oct 1];70(1):136–45. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283816002074.

  61. Del Río-Gonzalez S, Aragon IM, Castillo E, Milla-España F, Galacho A, Machuca J, et al. Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durability evaluation. Urology [Internet]. 2017 [cited 2018 Oct 1];108:52–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429517306969.

  62. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2):S216–23.

    CAS  PubMed  Google Scholar 

  63. Nitti VW, Ginsberg D, Sievert K-D, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol [Internet]. Elsevier. 2016 [cited 2018 Sep 30];196(3):791–800. Available from: https://www-sciencedirect-com.libproxy2.usc.edu/science/article/pii/S0022534716300945.

  64. Sun Y, Luo D, Tang C, Yang L, Shen H. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol [Internet]. 2015 [cited 2018 Sep 30];3:1779–88. Available from: https://search-proquest-com.libproxy2.usc.edu/docview/1728359169?accountid=14749.

  65. Yamanishi T, Kaga K, Fuse M, Shibata C, Uchiyama T. Neuromodulation for the treatment of lower urinary tract symptoms. LUTS Low Urin Tract Symptoms. 2015;7(3):121–32.

    Article  CAS  Google Scholar 

  66. Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol [Internet]. Elsevier Ltd. 2018;199(1):229–36. Available from: https://doi.org/10.1016/j.juro.2017.07.010.

  67. Abrams P, Cardozo L, Fall M, Gri D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;178:167–78.

    Article  Google Scholar 

  68. Stoffel J, Lightner D, Peterson A, Sandhu J, Suskind A, Wei J. Non-neurogenic chronic urinary retention: consensus definition, management strategies, and future opportunities [Internet]. 2016 [cited 2018 Oct 1]. Available from: https://www.auanet.org/guidelines/chronic-urinary-retention.

  69. Gross C, Habli M, Lindsell C, Al E. Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis. Female Pelvic Med Reconstr Surg. 2010;16:249.

    Article  Google Scholar 

  70. Patient resources — incontinence causes and treatments | National Association for Continence [Internet]. [cited 2018 Oct 1]. Available from: https://www.nafc.org/resource-center/.

  71. Home - your pelvic floor [Internet]. [cited 2018 Oct 1]. Available from: https://www.yourpelvicfloor.org/.

  72. Urinary incontinence - ACOG [Internet]. [cited 2018 Oct 1]. Available from: https://www.acog.org/Patients/FAQs/Urinary-Incontinence.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Alan Ginsberg .

Editor information

Editors and Affiliations

Commentary

Commentary

This is a very interesting case.

“A 45-year-old G2P2 obese woman with type 2 diabetes, hypertension, sleep apnea, and prior hysterectomy presents with urinary incontinence. She states her friend was cured with surgery, and she desires the same. She notes that her primary care provider had given her a medication that ‘didn’t work’ to reduce her leakage.”

The chapter presents a very thorough method for considering the problem of urinary incontinence and the treatment options for this lady. Importantly, the history, and physical exam as it pertains to incontinence, is carefully explained. Many of the various options for treatment of female incontinence are explained. However, when considering this particular case, a number of medical options need to be considered. The problem is that the case is very complex and multifaceted and that one or more factors need to be considered and each one needs to be eliminated or minimized to come to an acceptable treatment plan, which may take many months to execute completely, leading to an acceptable outcome for the patient.

One of the problems is that the lady in the case assumes that her incontinence has the same cause as her friend’s, and thus the procedure should fix her incontinence. This problem requires a lot of patience and education from the physician after a thorough evaluation to determine the precise cause(s) of this patient’s incontinence, with evaluation of her contributing factors, and thus realign her expectations with what is possible, and how she can be helped, and why her expectation of an operation may or may not work for her.

If one, at the outset, considers from the history:

Obesity: Is this severe? Does it contribute to metabolic syndrome? Is there a hormonal problem? Is it related to stress and overeating due to an anxiety disorder or prior psychological or physical trauma? It can add to stress incontinence if present on physical examination. Did she have Sheehan’s syndrome during childbirth, and is she now having problems with the treatment? Is what appears to be obesity really ascites or perhaps some large abdominal mass such as an ovarian cyst causing mass effect in the pelvis?

Diabetes: Is it well controlled? Does she have polyuria? Does she have peripheral neuropathy? Nephropathy with polyuria? Diabetic cystopathy? Are we assuming diabetes mellitus, where in fact she has diabetes insipidus due to lithium use for depression, which might be partly related to her incontinence? Is this diabetes insipidus contributing to her incontinence due to polyuria with urgency and inability to make it to the bathroom?

Hypertension: Is this being treated with diuretics? If so, the drug-induced increase in urine output can exacerbate her urgency and incontinence secondary to a more rapid filling of her bladder.

Sleep apnea: Is her incontinence nocturnal, thus related to untreated sleep apnea, with potential cardiac arrhythmias, and diuresis from ANF release?

G2P2: Was the bladder or pelvic floor injured during childbirth, and is there pudendal neuropathy or prolapse? The possibility of STDs with herpes lesions affecting bladder function might also be considered.

Prior hysterectomy: Is there subsequent prolapse contributing to incontinence, and is there neuropathy of the bladder due to interference with the pelvic nerves on the lateral fornixes innervating the bladder? Have there been other prior anti-incontinence procedures performed concurrently or subsequent to the hysterectomy? Is there a possible vesicovaginal fistula?

Medication that did not work: Was this something for overactive bladder or something different? Was it expected to work? Importantly, why did the medication “not work”? This would need to be explained to her.

In the background: With diabetes, obesity, and hypertension, and being female, is she at risk of serious cardiac event from a surgical procedure? Does she have adequate pulmonary status to manage anesthesia?

In the background: Does she potentially have spinal disorder, due to her obesity, and exacerbating degenerative disc disease, contributing to incontinence?

During the examination, many of these items can be assessed, but ultimately you have to decide whether the problem is related to polyuria, stress, urge, and mixed, overflow, or fistula incontinence or a combination. Each particular problem has to be addressed as a separate entity and treated as such. Ultimately this should be based on objective data and examination. Importantly as pointed out in this chapter, the use of urodynamics should explain the symptoms by the findings and not fit the findings to the symptoms.

This chapter is a great summary of available options to medically or surgically correct urinary incontinence which primarily impact patient’s quality of life. Did we write this section? I do not recall seeing this in the original chapter. So, with Dr. Lavelle also as an author, I am wondering if he was asked to write a summary of the chapter at the end (since he was otherwise not a co-author)? If so, ask him to work on this section. If not, please let me know and I will rewrite as it needs work. We must respect the patient’s rights to autonomy, self-determination, and freedom of will, to decide if and when they do or do not want any or all of these proposed or recommended procedures. However, this should be done in the circumstance of a full, frank, and open discussion(s) of the indications, nature of the treatment(s), and the risks, benefits, alternatives, and consequences of, and of not, performing each procedure as none are ideal. While we strive as physicians to make better options for our patients, they ultimately have to live with the consequences of these decisions. This is best if the patients can go into the procedure(s) “eyes wide open,” fully prepared, and comfortable with their decision, with the full support of their medical and caregiver teams. This is the final most important point of this chapter, where in the discussion of the case, the authors acknowledge the patient’s right to decline treatment.

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ginsberg, D.A., Horton, C.J. (2021). Overview of Treatment of Urinary Incontinence. In: Kobashi, K.C., Wexner, S.D. (eds) Female Pelvic Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-54839-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54839-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54838-4

  • Online ISBN: 978-3-030-54839-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics